498 related articles for article (PubMed ID: 21342321)
21. [Vitamin D therapy in predialysis renal failure].
Ando R
Clin Calcium; 2004 Sep; 14(9):73-7. PubMed ID: 15577115
[TBL] [Abstract][Full Text] [Related]
22. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
[TBL] [Abstract][Full Text] [Related]
23. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS
Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938
[TBL] [Abstract][Full Text] [Related]
24. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
[TBL] [Abstract][Full Text] [Related]
25. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
[TBL] [Abstract][Full Text] [Related]
26. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.
Hansen D; Rasmussen K; Pedersen SM; Rasmussen LM; Brandi L
Nephrol Dial Transplant; 2012 Jun; 27(6):2263-9. PubMed ID: 22140123
[TBL] [Abstract][Full Text] [Related]
27. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
28. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
29. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
[TBL] [Abstract][Full Text] [Related]
30. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
31. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O
Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
[TBL] [Abstract][Full Text] [Related]
32. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
[TBL] [Abstract][Full Text] [Related]
33. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
[TBL] [Abstract][Full Text] [Related]
35. [Attempt at evaluation of alfacalcidol administered by an oral pulsatile method to chronically dialysed patients with advanced secondary hyperparathyroidism].
Bunio A; Kwieciński R
Wiad Lek; 1994 May; 47(9-10):342-5. PubMed ID: 7817591
[TBL] [Abstract][Full Text] [Related]
36. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
37. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
38. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
Koskimies O; Ala-Houhala M
Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
Večerić-Haler Ž; Romozi K; Antonič M; Benedik M; Ponikvar JB; Ponikvar R; Knap B
Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912
[TBL] [Abstract][Full Text] [Related]
40. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]